Applied Finance Capital Management LLC Sells 764 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Applied Finance Capital Management LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,219 shares of the biopharmaceutical company’s stock after selling 764 shares during the quarter. Applied Finance Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $12,493,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Salomon & Ludwin LLC bought a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $31,000. Traub Capital Management LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $38,000. Berbice Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 87.5% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $780.28 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a market capitalization of $82.01 billion, a P/E ratio of 18.77, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The stock has a fifty day moving average of $757.89 and a 200-day moving average of $660.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $12.07 EPS. The firm’s revenue was up 2.5% compared to the same quarter last year. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on REGN shares. Canaccord Genuity Group upped their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. HSBC initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $255.00 price target for the company. Finally, Citigroup upped their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.